ADTX
Aditxt, Inc.
Key Financials
Operating Income
$-19570724
↑ 29.8%
Gross Profit
$268
↑ 100.1%
Net Income
$-43101451
↓ 6.8%
Revenue
$3195
↓ 97.6%
Total Assets
$16.5M
↓ 48.6%
Shareholders' Equity
$5.6M
↑ 1029.7%
Total Liabilities
$12.6M
↓ 47.3%
Cash & Equivalents
$833031.00
↑ 757.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 5/15/2026 | View on SEC |
| NT 10-Q | 5/15/2026 | View on SEC |
| 8-K | 5/8/2026 | View on SEC |
| 8-K | 5/1/2026 | View on SEC |
| 4 | 4/27/2026 | View on SEC |
| 424B3 | 4/23/2026 | View on SEC |
| 4 | 4/23/2026 | View on SEC |
| 3 | 4/23/2026 | View on SEC |
| EFFECT | 4/21/2026 | View on SEC |
| CORRESP | 4/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ADTX |
| Company Name | Aditxt, Inc. |
| CIK | 1726711 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 909-488-0844 |